Rapid Reactions

Guillermo Garcia-Manero, MD, from MD Anderson Cancer Center, characterizes the clinical outcome improvements observed with luspatercept for lower-risk myelodysplastic syndromes in clinical practice. View Video ›

Guillermo Garcia-Manero, MD, from MD Anderson Cancer Center, explores imetelstat trial results of patients with transfusion-dependent lower-risk myelodysplastic syndromes who experience failure to or are ineligible for treatment with erythropoiesis-stimulating agents. View Video ›

Guillermo Garcia-Manero, MD, from MD Anderson Cancer Center, explores imetelstat trial results of patients with transfusion-dependent lower-risk myelodysplastic syndromes who experience failure to or are ineligible for treatment with erythropoiesis-stimulating agents. View Video ›

Please join Guillermo Garcia-Manero, MD, from MD Anderson Cancer Center, as he discusses how the clinical benefits of luspatercept could lead to a new standard of care for patients with transfusion-dependent lower-risk myelodysplastic syndromes. View Video ›